Medications and reimbursement status at baseline by living arrangement status
| Living alone (n=3648) | Not living alone (n=28 728) | P value | |
| Medication, n (%) | |||
| Aspirin | 3154 (86.5) | 25 257 (87.9) | 0.011 |
| Thienopyridine | 835 (22.9) | 7944 (27.7) | <0.001 |
| Other antiplatelets | 291 (8.0) | 2695 (9.4) | 0.006 |
| ≥2 antiplatelets | 3644 (99.9) | 28 721 (99.9) | <0.001 |
| Oral anticoagulants | 299 (8.2) | 2331 (8.1) | 0.87 |
| Beta-blockers | 2652 (72.7) | 21 718 (75.6) | <0.001 |
| Symptoms indicative of intolerance or contraindication to beta-blockers | 516 (14.2) | 4167 (14.5) | 0.56 |
| Ivabradine | 330 (9.1) | 2873 (10.0) | 0.069 |
| Calcium antagonists | 1057 (29.0) | 7765 (27.0) | 0.012 |
| ACE inhibitor or ARB | 2790 (76.5) | 21 902 (76.2) | 0.73 |
| Lipid-lowering drugs | 3301 (90.5) | 26 598 (92.6) | <0.001 |
| Statins | 2954 (81.0) | 23 886 (83.2) | 0.001 |
| Long-acting nitrates | 764 (21.0) | 6313 (22.0) | 0.16 |
| Other antianginal agents | 491 (13.5) | 4030 (14.0) | 0.36 |
| Diuretics | 3154 (86.5) | 25 257 (88.0) | 0.011 |
| Other antihypertensive agents | 283 (7.8) | 1946 (6.8) | 0.027 |
| Digoxin and derivatives | 108 (3.0) | 706 (2.5) | 0.067 |
| Amiodarone/dronedarone | 111 (3.0) | 835 (2.9) | 0.64 |
| Other antiarrhythmics | 46 (1.3) | 260 (0.9) | 0.036 |
| NSAIDs | 237 (6.5) | 1350 (4.7) | <0.001 |
| Antidiabetic agents | 802 (23.0) | 7126 (24.8) | <0.001 |
| Proton-pump inhibitors | 987 (27.1) | 7029 (24.5) | <0.001 |
| Thyroid HRT | 263 (7.2) | 1144 (4.0) | <0.001 |
| HRT in postmenopausal women | 16 (0.4) | 82 (0.3) | 0.11 |
| Erectile dysfunction | 60 (2.7) | 459 (2.0) | 0.04 |
| Reimbursement of cardiovascular agents, n (%) | <0.001 | ||
| Fully reimbursed | 1612 (44.3) | 11 044 (38.5) | |
| Partly reimbursed | 1363 (37.5) | 10 880 (37.9) | |
| Not reimbursed | 665 (18.3) | 6786 (23.6) |
ARB; angiotensin II receptor block; HRT, hormone replacement theory.